Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors

PURPOSE: At present, there are no validated biomarkers that can predict whether patients with advanced hepatocellular carcinoma (aHCC) are likely to benefit from anti-PD-1 therapy. We aimed to determine whether lung immune prognostic index (LIPI) is associated with outcomes in patients with aHCC tre...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Hepatocell Carcinoma
Главные авторы: Chen, Shixue, Huang, Ziwei, Jia, Wangping, Tao, Haitao, Zhang, Sujie, Ma, Junxun, Liu, Zhefeng, Wang, Jinliang, Wang, Lijie, Cui, Pengfei, Zhang, Zhibo, Huang, Di, Wu, Zhaozhen, Zheng, Xuan, Hu, Yi
Формат: Artigo
Язык:Inglês
Опубликовано: Dove 2020
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7646485/
https://ncbi.nlm.nih.gov/pubmed/33173757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S277453
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы